Social Aspects of Drug Discovery, Development and Commercialization. Questo articolo non è disponibile.Social Aspects of Drug Discovery, Development and Commercialization

Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process. This book provides thoughtful and valuable discussions and analysis of the social challenges and potential opportunities through all stages of the pharmaceutical process, from inception through marketing. With a unique focus on the social factors that increasingly play a role in how drug development is planned, structured, and executed throughout the drug product lifecycle, this is an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society.

Dr. Odilia Osakwe has published 25 titles, including 1 book (edited), 24 articles in peer reviewed platform including journal articles, scholarly magazines, newsletters and technical notes. And has authored 10 papers/posters and oral presentations in major international professional meetings. Odilia has reviewed numerous manuscripts for different academic journals. Aside from those activities, she served as an editorial board member with Pharmaceutical Science Group of Canada for 3 years reviewing and editing articles with active contribution towards several of the published front cover topics. Odilia received her undergraduate degree from Abia state University and her Masters in Chemistry from Tennessee State University. Within this period, she worked with the Tennessee State Department of Laboratory Services. Following completion of a Master Degree in Chemistry, she took on a two-year post graduate fellowship, which was granted by Vanderbilt University, Nashville, Tennessee; completed in the department of pharmacology of Vanderbilt University Medical Centre. She joined a doctoral program with the department of pharmaceutical Sciences of Mercer University, Atlanta, Georgia and earned a PhD degree. During much of this period, starting from the second year into the doctoral program, she joined the Georgia Perimeter College, Atlanta, Georgia, teaching Chemistry courses for two years till the end of the program. During the all-but-dissertation stage, (ABD), Odilia received a Student Research Fellowship with the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia where she worked as a researcher with the immunology laboratories of National Center for Immunization and Respiratory Diseases (NCIRD) in the Division of Bacterial Diseases (DBD), using the state-of-the-art instrumentation for validation of immunological assays. Further on, Odilia received a competitive National Science and Engineering Research Council of Canada (NSERC) award for Industrial Research and Development Postdoctoral Fellowship (IRDF-NSERC). The two-year training was accomplished at the University of Toronto Hospital Network, Industrial BioDevelopment Laboratory (IBDL) department where she took the lead of the Research and Development activities which include technical oversight and training of the University of Toronto undergraduates on various projects, with published results. Odilia works with Devik Pharma Inc., also a board member of the North American Institute of Pharmaceutical Technology, Scarborough, Ontario, Canada where she undertakes administrative and scholarly duties in the industrial pharmaceutical sector. She is an Adjunct Faculty with Ryerson University, Toronto, Ontario, Canada and Seneca College of Arts and Technology, Toronto, Ontario, Canada, teaching several courses in the Industrial Pharmaceutical Technology program.

Dr. Rizvi is a highly accomplished scientist, clinician, and academic leader with more than two decades of multidisciplinary experience spanning pharmaceutical sciences, clinical research, regulatory affairs, and healthcare delivery. He brings over 11 years of industry experience across both leadership and bench research roles, together with more than 23 years of peer-reviewed scientific writing and extensive expertise in drug discovery, development, and commercialization.

Throughout his career, Dr. Rizvi has demonstrated leadership in clinical trials across all phases and has significant experience in regulatory submissions, including IND, NDA, and eCTD dossiers. He has also led work in pharmacovigilance and the establishment of Good Clinical Practice (GCP)-compliant quality systems.

Dr. Rizvi is an internationally recognized scholar with 291 peer-reviewed publications, including books, book chapters, patents, and conference presentations, which have been cited more than 7,200 times. He has also served in over 440 editorial and peer-review roles across more than 300 scientific journals and publishers.

His technical expertise spans medicinal chemistry, pharmaceutical formulation, analytical sciences, nanotechnology, vaccine development, and natural products research. In addition to his research contributions, Dr. Rizvi has extensive experience in academic teaching and mentorship, clinical practice as a registered nurse, and translational research. He has a strong record of training graduate students, securing research funding, and advancing inclusive, patient-centered care across diverse healthcare settings.